Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors. - Wikidata - wikimedia - TriplyDB

Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.

Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.

http://www.wikidata.org/entity/Q34717844

about

Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.Anthracycline induced cardiotoxicity: biomarkers and "Omics" technology in the era of patient specific care.Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at hig Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients Echocardiographic Detection of Cardiac Dysfunction in Childhood Cancer Survivors: How Long Is Screening Required?Roadmap for biomarkers of cancer therapy cardiotoxicity.The Role of Biomarkers in Detection of Cardio-toxicity.Cardiomyopathy in Childhood Cancer Survivors: Lessons from the Past and Challenges for the Future.Screening and intervention for treatment-related cardiac dysfunction in childhood cancer survivors.Chemotherapy-induced cardiotoxicity in children.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma.Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment.

P2860

Q30248340-E217E430-A65F-4934-86C6-B642B627A520 Q33658456-C6D5A3BE-9062-4469-B1E2-62A5A8D5810C Q36156912-D50D4B34-CD89-4A7B-995F-A07392AF3CA4 Q36181301-1333E046-12FD-43DA-893E-4277E818B645 Q36348525-C0B2D23F-F567-49F3-8B2D-B9780E01C76C Q36626934-105E4EA0-0FA8-4623-903C-6F87BF97B8BD Q38728535-36ACF722-FAA8-4A02-A51C-008F597CC75E Q38753035-706B95B9-2C9D-4BA3-ABF2-4EAB0D7AB23F Q38982295-51B34B9A-4711-4620-9B21-040055428DD2 Q39415815-1D9BD8E2-247C-43A1-A7E0-EB7383FA6554 Q45073135-85F52034-FE63-44EF-8C9C-70318040443C Q46004410-2365DE14-1ABA-43BC-B5F0-625E938D3EFB Q55429574-8F4295A7-A19B-4DDB-BC87-7ADEF75CB8BD

P2860

Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.

http://www.wikidata.org/entity/Q34717844

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.

@ast

Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.

@en

Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.

@nl

type

label

Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.

@ast

Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.

@en

Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.

@nl

prefLabel

Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.

@ast

Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.

@en

Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.

@nl

P1433

Q34717844-064D2A48-C917-4A7F-AC9D-AD05C9FA538B

P1476

Q34717844-7F82E788-1597-48D4-B51B-F861A4C21C4B

P2093

Q34717844-232217C0-C3CD-49AF-A66E-DE4EAC5BF8EA

Q34717844-33688B68-3AC3-4D9C-A044-184490DD8354

Q34717844-35CBAE75-9C9B-4DE0-8EF1-3E1645E3D546

Q34717844-3AF899F7-51CC-4216-B37E-F07F00ED4A17

Q34717844-3D28D734-6CA5-4582-ADDD-B62F3A1506E2

Q34717844-5CDA96C6-A049-46DE-B218-95C16F10585F

Q34717844-602F70E1-7E64-4E30-8399-9EB831BE6F27

Q34717844-75CF6AF7-EE1D-410C-A161-97A955302F4E

Q34717844-84A9DA1B-8D8F-4481-8042-58B0587A0A35

Q34717844-AD71DBFB-1655-4D99-B5BA-00B3A96973E3

P2860

Q34717844-02312B5F-9576-4F63-B06C-2063FD2521F7

Q34717844-05E93684-70FF-4E33-A5DD-3546183C14F0

Q34717844-074DD1BA-3A81-4A2D-B539-8F3E0856E8CA

Q34717844-12D2B0E5-8B71-4017-ADD0-2A7E2DDE6F0A

Q34717844-1C32DA40-C949-49AC-A4B6-2E55C5FA312D

Q34717844-23591CE4-1775-469C-A22D-F1A2C2C446D1

Q34717844-25EB669B-4DCE-4442-9E7D-B453599A5F88

Q34717844-33E6AF1B-1334-4A7E-9E53-7761035A2575

Q34717844-3D4D3930-B98B-4B53-90E1-A6B4D488E9D6

Q34717844-43AF836B-DAF8-42D2-B6EF-ED2026762E19

P304

Q34717844-D15291A9-0AE1-44D3-B1A9-B811D2A8E990

P31

Q34717844-30003C3A-F58B-46EF-B3AA-42FC855EDBE1

P356

Q34717844-3D5FCEDD-FB9E-4F71-973E-F4271A830F1A

P407

Q34717844-6E9392B5-BE0B-4A9F-A24E-474F5586D851

P433

Q34717844-47185512-872D-48DD-B5B2-5E4984ACCFE4

P478

Q34717844-99816A3B-E7B8-4D81-A120-F3173ADCE324

P577

Q34717844-FA76550B-8946-4E60-8EB6-15196127BE96

P698

Q34717844-4B584B5F-B973-406A-834A-00A20D54E4DF

P932

Q34717844-C362DF6E-68BD-4428-A435-60E6D42FC1AD

P356

1078-0432.CCR-13-3490

P1433

Clinical Cancer Research

P1476

Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.

@en

P2093

Claudia Herrera

http://www.w3.org/2001/XMLSchema#string

David R Freyer

http://www.w3.org/2001/XMLSchema#string

John-David Menteer

http://www.w3.org/2001/XMLSchema#string

Kalyanasundaram Venkataraman

http://www.w3.org/2001/XMLSchema#string

Karla D Wilson

http://www.w3.org/2001/XMLSchema#string

Leah Reichman

http://www.w3.org/2001/XMLSchema#string

Leo Mascarenhas

http://www.w3.org/2001/XMLSchema#string

Rajkumar Venkatramani

http://www.w3.org/2001/XMLSchema#string

Sarah K Gelehrter

http://www.w3.org/2001/XMLSchema#string

Saro H Armenian

http://www.w3.org/2001/XMLSchema#string

P2860

Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging.

The ventricular volume variability study of the Pediatric Heart Network: study design and impact of beat averaging and variable type on the reproducibility of echocardiographic measurements in children with chronic dilated cardiomyopathy.

Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.

Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention.

Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy.

Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group.

Late congestive heart failure after hematopoietic cell transplantation

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

Detection and prevention of cardiac complications of cancer chemotherapy.

Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity.

P304

6314-6323

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-3490

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24947931

http://www.w3.org/2001/XMLSchema#string

P932

4268342

http://www.w3.org/2001/XMLSchema#string